# Guardant Health

Guardant Health secured the first FDA-approved liquid biopsy for non-small cell lung cancer (NSCLC) profiling.

Source: https://en.bioecon.ru/companies/guardant-health/
Updated: 2026-07-02

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Capacity | Accelerated investment in laboratory capacity ongoing as of 2026 to support volume growth | https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Health-Reports-Second-Quarter-2026-Financial-Results-and-Increases-2026-Revenue-Guidance/default.aspx, https://www.sdbj.com/news/enews/guardant-health-scaling-san-diego/ |
| Certification | CLIA certified, CAP accredited, and licensed in California, New York, and other states | https://www.sec.gov/Archives/edgar/data/1576280/000119312526187423/d68529dars.pdf |
| Regulatory approval | FDA approval for Guardant360 Liquid CDx (May 2026), Guardant360 CDx (2020), and Shield blood test (2024) | https://investors.guardanthealth.com/press-releases/press-releases/2020/Guardant-Health-Guardant360-CDx-First-FDA-Approved-Liquid-Biopsy-for-Comprehensive-Tumor-Mutation-Profiling-Across-All-Solid-Cancers/default.aspx, https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant360-CDx-Receives-FDA-Approval-as-First-and-Only-Liquid-Biopsy-Companion-Diagnostic-for-Amgens-LUMAKRAS-sotorasib-KRASG12C-Inhibitor-for-Use-in-Advanced-Non-Small-Cell-Lung-Cancer/default.aspx, https://investors.guardanthealth.com/press-releases/press-releases/2026/FDA-Approves-New-Guardant360-Liquid-CDx-the-Largest-FDA-Approved-Liquid-Biopsy-Panel-with-a-100x-Expanded-Footprint/default.aspx, https://www.sec.gov/Archives/edgar/data/1576280/000119312526187423/d68529dars.pdf |
| Production site | Laboratories in Redwood City, California (HQ); San Diego, California; Long Island City, New York; and Palo Alto, California (CLIA licensed) | https://www.sdbj.com/news/enews/guardant-health-scaling-san-diego/, https://www.sec.gov/Archives/edgar/data/1576280/000119312526187423/d68529dars.pdf |
| Revenue | $982 million in 2025 | https://www.businesswire.com/news/home/20260219448137/en/Guardant-Health-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-2026-Outlook, https://www.medicaldevice-network.com/news/fda-approves-guardant-health-next-generation-liquid-biopsy-panel/ |

Independent sources: businesswire.com, medicaldevice-network.com, sdbj.com, sec.gov

## Technologies

- [Liquid biopsy & ctDNA diagnostics](https://en.bioecon.ru/technology/liquid-biopsy-ctdna-diagnostics/)
- [Personalized diagnostics](https://en.bioecon.ru/technology/personalized-diagnostics/)